glp 1 and gip dual agonist Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Cardiorenal Outcomes With GLP-1 vs.

It cannot distinguish between properly folded and misfolded peptides

To determine the site of action in the brain that GLP-1 and Gcg coagonism may be occurring, one group examined c-fos induction upon co-injection of GLP-1 and Gcg (Parker et al., 2013)

The disadvantage here is that one cannot distinguish between direct effects of the KO and side effects caused, for example, by different immune cell status or decreased caloric intake

The concept of incretin effect was first proposed by Creutzfeldt in the 1970s ( 2 Physiology of incretins 2.1 Discoveries of GIP and GLP-1 The first incretin, GIP, was purified from canine intestinal extracts in the late 1960s ( + secretion ( Figure 1 Section A]

Medical professionals must recognize these potential side effects to diagnose them promptly and intervene correctly, which helps achieve the best patient safety and treatment results